Insulin-like growth factor-1 abrogates microglial oxidative stress and TNF-α responses to spreading depression

Yelena Y Grinberg1, Megan E Dibbern, Victoria A Levasseur

  • 1Department of Neurology, The University of Chicago Medical Center, Chicago, Illinois 60637-1470, USA.

Insights

Spreading depression (SD), linked to migraines, involves oxidative stress (OS) and inflammation. Microglia cells drive this process via reactive oxygen species (ROS) and tumor necrosis factor-alpha (TNF-α), suggesting IGF-1 as a potential therapeutic target.

Area of Science:

  • Neuroscience
  • Cell Biology

Background:

  • Spreading depression (SD) is implicated in migraine aura and pathogenesis.
  • SD is associated with increased oxidative stress (OS) and neuronal excitability.
  • Tumor necrosis factor-alpha (TNF-α) is elevated by SD and increases neuronal excitability.

Purpose of the Study:

  • To investigate the cellular origin of oxidative stress (OS) during spreading depression (SD).
  • To explore the relationship between SD-induced OS and tumor necrosis factor-alpha (TNF-α).
  • To determine the role of insulin-like growth factor-1 (IGF-1) in mitigating SD-associated OS and TNF-α.

Main Methods:

  • Utilized rat hippocampal slice cultures to study spreading depression (SD).
  • Measured oxidative stress (OS) in different cell types (neurons, astrocytes, microglia, oligodendrocytes).
  • Assessed the effects of insulin-like growth factor-1 (IGF-1) and tumor necrosis factor-alpha (TNF-α) on OS and SD susceptibility.

Main Results:

  • SD significantly increased OS in astrocytes and microglia, but not in neurons or oligodendrocytes.
  • IGF-1 administration reduced microglial OS and abrogated SD-induced TNF-α increase.
  • TNF-α application elevated microglial OS, an effect blocked by IGF-1.
  • SD enhanced its own susceptibility through TNF-α signaling.

Conclusions:

  • Microglia are identified as key players in promoting SD through interconnected ROS and TNF-α signaling.
  • IGF-1 demonstrates potential therapeutic value by mitigating microglial ROS and TNF-α responses.
  • Targeting microglial pathways offers a novel strategy for developing therapeutics for SD and potentially migraines.

Related Concept Videos